In the EU, where biosimilars have hit hard, Roche was finally able to turn up sales growth in Q3 after several quarters of decline. All told, newer drugs including hemophilia A therapy Hemlibra, multiple sclerosis blockbuster Ocrevus and PD-L1 inhibitor Tecentriq helped contribute $3.94 billion additional sales in the first nine months of 2019 over the same period last year, more than enough to offset the $1.02 billion blow from biosims. Thanks to the strong momentum of those medicines and the better-than-expected biosim situation, Roche's pharma division racked up $12.4 billion in sales in Q3, 15% ahead of last year's tally and beating the Street's consensus by 3.2%.